J Geisler
Overview
Explore the profile of J Geisler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
761
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ohnstad H, Blix E, Akslen L, Gilje B, Raj S, Skjerven H, et al.
ESMO Open
. 2024 Jun;
9(6):103475.
PMID: 38838499
Background: EMIT-1 is a national, observational, single-arm trial designed to assess the value of the Prosigna, Prediction Analysis of Microarray using the 50 gene classifier (PAM50)/Risk of Recurrence (ROR), test...
2.
Mecinaj A, Gulati G, Heck S, Holte E, Fagerland M, Larsen A, et al.
Cardiooncology
. 2021 Sep;
7(1):33.
PMID: 34579775
Background: Recent advances in the treatment algorithms of early breast cancer have markedly improved overall survival. However, anthracycline- and trastuzumab-associated cardiotoxicity may lead to dose-reduction or halt in potentially life-saving...
3.
Eikesdal H, Yndestad S, Elzawahry A, Llop-Guevara A, Gilje B, Blix E, et al.
Ann Oncol
. 2020 Nov;
32(2):240-249.
PMID: 33242536
Background: The antitumor efficacy of PARP inhibitors (PARPi) for breast cancer patients harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi monotherapy was ineffective in patients with metastatic triple...
4.
Ny L, Hernberg M, Nyakas M, Koivunen J, Oddershede L, Yoon M, et al.
Acta Oncol
. 2020 Apr;
59(7):833-844.
PMID: 32285732
The analysis of the BRAF mutational status has been established as a standard procedure during diagnosis of advanced malignant melanoma due to the fact that BRAF inhibitors constitute a cornerstone...
5.
Birkeland E, Zhang S, Poduval D, Geisler J, Nakken S, Vodak D, et al.
Nat Commun
. 2018 Jul;
9(1):2665.
PMID: 29991680
Genomic alterations occurring during melanoma progression and the resulting genomic heterogeneity between metastatic deposits remain incompletely understood. Analyzing 86 metastatic melanoma deposits from 53 patients with whole-exome sequencing (WES), we...
6.
Kekow J, Wiedemann G, Katschinski D, Kisro J, Geisler J, Wagner T, et al.
Int J Oncol
. 2011 May;
7(6):1427-32.
PMID: 21552983
The low bone marrow toxicity of high dose alkylating agents when given in combination with whole body hyperthermia (WBH) may be explained in part by the parallel induction of the...
7.
Geisler J
Br J Cancer
. 2011 Mar;
104(7):1059-66.
PMID: 21364577
Aromatase inhibition is the gold standard for treatment of early and advanced breast cancer in postmenopausal women suffering from an estrogen receptor-positive disease. The currently established group of anti-aromatase compounds...
8.
Kunz M, Thon N, Eigenbrod S, Hartmann C, Egensperger R, Herms J, et al.
Neuro Oncol
. 2011 Feb;
13(3):307-16.
PMID: 21292686
Molecular imaging studies have recently found inter- and intratumoral heterogeneity in World Health Organization (WHO) grade II gliomas. A correlative analysis with tumor histology, however, is still lacking. For elucidation...
9.
Weiss C, Witt T, Fesl G, Geisler J, Tonn J
Fortschr Neurol Psychiatr
. 2010 Mar;
78(3):154-60.
PMID: 20213581
Angiographic Moyamoya is a rare cerebrovascular disease most frequent in asia. Its characateristics are recurrent ischemic attacks due to progressive occlusion of ICA branches. Angiography reveals fine arterial collateralisation reminding...
10.
Lonning P, Geisler J
J Steroid Biochem Mol Biol
. 2009 Oct;
118(4-5):288-93.
PMID: 19808096
Development of aromatase inhibition and aromatase inhibitors as a therapeutic strategy was initiated through two different pathways. The one pathway went through systematic exploration of aromatase substrate analogues for enzyme...